Subtype
High Grade Astrocytic Tumor
CI-CAN-00005503Explore in graph →
495 active trials2 approved drugs51 evidence items
- NCIt
- C102897
Loading cancer entity…
Subtype
CI-CAN-00005503Explore in graph →
Clinical trials
1,778 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (282)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07387666 | Imaging Acetadote Metabolism in Glioblastoma | recruiting | Early Phase 1 | 10 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07392957 | Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 54 | Washington University School of MedicineOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07375992 | Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)(MELODY) | recruiting | N/A | 35 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07655869 | [177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma | recruiting | Early Phase 1 | 24 | Beijing Tiantan HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07541781 | Sitagliptin in Recurrent/Progressive Grade 4 Glioma | recruiting | Phase 1 | 45 | Kailin Yang, MD, PhDOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07648823 | Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma | recruiting | Early Phase 1 | 5 | Beijing Tiantan HospitalOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04323046 | Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | active not recruiting | Phase 1 | 9 | Sabine Mueller, MD, PhDOTHER | 2 | Jun 15, 2026 | clinicaltrials |
| NCT07346144 | Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma(ADePT) | recruiting | Phase 1 / Phase 2 | 68 | Trogenix ltdINDUSTRY | 2 | Jun 12, 2026 | clinicaltrials |
| NCT07422363 | Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma | not yet recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 0 | Jun 12, 2026 | clinicaltrials |
| NCT07643870 | Human ADME Study of [14C]-AZD1390 | not yet recruiting | Phase 1 | 8 | AstraZenecaINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04732065 | ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors(PNOC023) | recruiting | Phase 1 | 208 | Sabine Mueller, MD, PhDOTHER | 3 | Jun 11, 2026 | clinicaltrials |
| NCT05283330 | Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | recruiting | Phase 1 | 48 | Orano Med Theranostics, SASINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06622434 | New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study(NAVIG-1) | recruiting | Phase 1 / Phase 2 | 35 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05053880 | A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme | active not recruiting | Phase 1 / Phase 2 | 48 | Accendatech USA Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07634575 | Triggered Imaging in Glioblastoma Based on Clinical Outcome Evaluation Compared to Routine: a Feasibility Study(TIGER F) | enrolling by invitation | N/A | 20 | King's College Hospital NHS TrustOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07636200 | The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer(EASE) | recruiting | N/A | 250 | University of Colorado, BoulderOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT04545177 | Improving Understanding of Brain Tumors Through Preservation of Biologically Active Brain Tissue | active not recruiting | N/A | 18 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05904119 | Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study(LEGATO) | recruiting | Phase 3 | 411 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 11 | Jun 8, 2026 | clinicaltrials |
| NCT06011109 | Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab | recruiting | Phase 1 / Phase 2 | 30 | Aveta Biomics, Inc.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07274397 | Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma(EARLYBRAINPET) | recruiting | N/A | 15 | Beta Emitting Accurate Monitored SystemsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT02649582 | Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients(ADDIT-GLIO) | active not recruiting | Phase 1 / Phase 2 | 20 | University Hospital, AntwerpOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07223034 | A Study of 177Lu-PSMA-617 in People With Gliomas | recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07274787 | Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma | not yet recruiting | N/A | 10 | University of CincinnatiOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07627334 | Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial In Patients Scheduled for shOrt Course radiatioN(ATTRACTION) | recruiting | N/A | 30 | Medical University of ViennaOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07628257 | Cerebral Connectivity and Metabolic Phenotype of Gliomas: Prospective Addition of DTI and Rs-fMRI to a Preoperative FDG PET Strategy, With Neuropsychological Correlates and Post-treatment Follow-up(GlioConnect) | not yet recruiting | N/A | 80 | Centre Paul StraussOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04780009 | Loupe-Based Intraoperative Fluorescence Imaging | recruiting | — | 30 | Guoqiang YuOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04978727 | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | active not recruiting | Phase 1 | 35 | Children's Oncology GroupNETWORK | 2 | Jun 2, 2026 | clinicaltrials |
| NCT06533163 | Low-Intensity Oscillatory Magnetic Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) - An Exposure-time Escalation Pilot Trial(OMX-EFS-01) | recruiting | N/A | 30 | BioTex, Inc.INDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07620548 | Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas | not yet recruiting | Phase 2 | 99 | Washington University School of MedicineOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT01269853 | Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA | recruiting | Phase 1 / Phase 2 | 54 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02861898 | Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 33 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03213002 | Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM(CAPTEM) | recruiting | Phase 1 / Phase 2 | 67 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05271240 | Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | recruiting | Phase 3 | 432 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05954858 | Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma | recruiting | N/A | 32 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05979064 | Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM) | recruiting | N/A | 10 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07616986 | LITT for Ultra-early GBM Recurrence | recruiting | N/A | 12 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05116137 | The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors(RESIST) | enrolling by invitation | N/A | 24 | Nova Scotia Health AuthorityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05843253 | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant | recruiting | Phase 2 | 120 | Nationwide Children's HospitalOTHER | 6 | May 29, 2026 | clinicaltrials |
| NCT06831526 | Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma | recruiting | Early Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06264388 | DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma | recruiting | Phase 2 | 33 | Ashish ShahOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT04752280 | Glioblastoma Radiotherapy Using IMRT or Proton Beams(GRIPS) | recruiting | N/A | 326 | University Hospital HeidelbergOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07605364 | Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer | not yet recruiting | Phase 2 / Phase 3 | 422 | Alliance for Clinical Trials in OncologyOTHER | 0 | May 26, 2026 | clinicaltrials |
| NCT03688178 | DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab(DERIVe) | active not recruiting | Phase 2 | 43 | Annick Desjardins, MDOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05736406 | A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 12 | Hemerion TherapeuticsINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT07411690 | Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial Tumors(CSF-IMR) | recruiting | — | 200 | Medical University of WarsawOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07604285 | A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma(NOVA-GBM) | not yet recruiting | Phase 1 / Phase 2 | 36 | Myosin Therapeutics Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07413796 | Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted Sutures(NEURO-SUTURE) | recruiting | N/A | 382 | Medical University of WarsawOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05500612 | MRI Hypoxia Study for Glioblastoma Multiforme (GBM) Radiation Therapy(MANGO) | recruiting | — | 20 | University of SydneyOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07590726 | PIRe 2.0: A Stepped-Care Model for Involving Relatives Across Sectors(PIRe) | not yet recruiting | N/A | 160 | Rigshospitalet, DenmarkOTHER | 1 | May 19, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 23, 2026source: clinicaltrials